Common arm analysis: One approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer
- 1 August 2006
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 53 (2) , 157-164
- https://doi.org/10.1016/j.lungcan.2006.05.007
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Front-line paclitaxel–vinorelbine versus paclitaxel–carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trialAnnals of Oncology, 2004
- Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1Journal of Clinical Oncology, 2004
- Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2Journal of Clinical Oncology, 2004
- Phase III Randomized Trial of Docetaxel Plus Cisplatin Versus Vindesine Plus Cisplatin in Patients With Stage IV Non-Small-Cell Lung Cancer: The Japanese Taxotere Lung Cancer Study GroupJournal of Clinical Oncology, 2004
- Projection of lung cancer mortality in JapanCancer Science, 2003
- Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study GroupJournal of Clinical Oncology, 2003
- Paclitaxel Plus Carboplatin Versus Gemcitabine Plus Paclitaxel in Advanced Non–Small-Cell Lung Cancer: A Phase III Randomized TrialJournal of Clinical Oncology, 2002
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Novel combination chemotherapy in the treatment of non-small cell lung cancerExpert Opinion on Pharmacotherapy, 2000
- Response rate as an endpoint for evaluating new cytotoxic agents in phase II trials of non-small-cell lung cancerAnnals of Oncology, 1998